NTRB
Nutriband Inc.4.4900
-0.3500-7.23%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
54.58MP/E (TTM)
-Basic EPS (TTM)
-3.05Dividend Yield
0%Recent Filings
8-K
Nutriband kills Pocono sale
Nutriband terminated its agreement to sell subsidiary Pocono Pharmaceuticals to Earth Vision Bio immediately after the buyer's failure to close by December 31, 2025, and pay late fees beyond the $30,000 already received. No further payments arrived since January 21, 2026. Deal's dead. Board acted February 13, 2026, retaining the asset amid buyer default.
8-K
Shareholders approve all; board expands.
Nutriband's stockholders overwhelmingly approved all proposals at its January 24, 2026 annual meeting, reelecting seven directors with 86-88% support and ratifying Sadler Gibb as 2025 auditor. They boosted authorized preferred shares from 10M to 20M and backed exec pay. Board then added finance expert Alessandro Puddu and aviation manager Viorica Carlig. New directors strengthen governance.
8-K
Sells 90% Pocono for $5M
Nutriband signed an agreement on December 29, 2025, to sell 90% of subsidiary Pocono Pharmaceuticals to EarthVision Bio for $5M USD, retaining a 10% stake; closing expected December 31. Proceeds will fund AVERSA Fentanyl development, an abuse-deterrent opioid patch. Deal sharpens focus. Forward-looking sales potential cited, but risks abound.
10-Q
Q3 FY2026 results
Nutriband's Q3 FY2026 revenue fell 46% y/y to $346K from Pocono Pharmaceuticals while YTD sales rose 9% y/y to $1.6M, with gross margins expanding to 19.8% from 29.6% q/q (derived). Operating losses widened to $3.9M from $1.4M y/y, driven by $3.5M SG&A and $457K R&D on Aversa Fentanyl versus prior-year levels; net loss hit $3.9M or ($0.32) per share on 12.1M diluted shares, consistent with calculation. Cash swelled to $5.3M on $5.4M warrant exercises, funding $4.4M operating burn; free cash flow not disclosed in the 10-Q. Debt stays low at $170K. Ongoing Gunnar lawsuit risks distraction.
8-K
FDA greenlights Nutriband's fentanyl patch plans
Nutriband Inc. completed a key FDA meeting on September 18, 2025, securing feedback on CMC plans for its AVERSA FENTANYL abuse-deterrent patch, confirming the 505(b)(2) NDA pathway and guidance on manufacturing validation and abuse studies. The company now integrates this input toward an IND filing for a Human Abuse Potential study, partnering with Kindeva to address fentanyl patch risks like misuse and accidental exposure. FDA's support highlights the unmet need. No abuse-deterrent fentanyl patch exists yet.
ASBP
Aspire Biopharma Holdings, Inc.
0.10-0.00
ATXI
Avenue Therapeutics, Inc.
0.67+0.02
BSEM
BioStem Technologies, Inc.
3.84-0.11
DRUG
Bright Minds Biosciences Inc.
93.99+8.32
ENDV
Endonovo Therapeutics, Inc.
0.00+0.00
ENSC
Ensysce Biosciences, Inc.
1.18-0.07
ENVB
Enveric Biosciences, Inc.
5.24-0.12
LPCN
Lipocine Inc.
3.15+0.00
NRXP
NRX Pharmaceuticals, Inc.
2.10+0.12
NTRR
Neutra Corp.
0.00+0.00